Wells Fargo raised the firm’s price target on CVS Health (CVS) to $84 from $76 and keeps an Overweight rating on the shares. The firm notes CVS beat Q1 and increased guidance, but has modestly underperformed despite what Wells saw as a very constructive update. The firm thinks uncertainty around earnings quality is likely why.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $81 from $74 at RBC Capital
- CVS Health price target raised to $95 from $90 at TD Cowen
- Cigna price target raised to $390 from $379 at Morgan Stanley
- CVS Health’s Positive Trajectory: Outperform Rating Reaffirmed with Raised Price Target
- CVS Health price target raised to $71 from $67 at UBS